Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1/2 2Phase NA 1Phase 4 1Phase 1 1

Status

Recruiting 3Unknown 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Lymphoma 1Carcinoma, Squamous Cell 1

Interventions

Cyclophosphamide 37Gemcitabine 31Paclitaxel 28Cisplatin 28Carboplatin 27Capecitabine 27camrelizumab 25Nivolumab 24apatinib 23Oxaliplatin 21fludarabine 20Radiotherapy 20toripalimab 19Drug Therapy 18Immunotherapy, Adoptive 17pembrolizumab 16Docetaxel 16Bevacizumab 16Dexamethasone 15N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Injections 14tislelizumab 13Temozolomide 13Rituximab 13Cetuximab 13Irinotecan 12Fluorouracil 11130-nm albumin-bound paclitaxel 11anlotinib 10Trastuzumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Unknown × penpulimab × Clear all
NCT05783921 2023-07-28

A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Unknown
60 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05400876 2023-02-14

To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Unknown
92 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡